Sarepta疗法 SRPT 深 沪
等待开盘 03-27 09:30:00 美东时间
21.68
-2.090
-8.79%
华盛通- 最 高23.85
- 今 开23.15
- 成交量 751.28万股
- 最 低 15.525
- 昨 收 23.77
- 总市值 189.70万
- 52周最高 64.80
- 市盈率 静 --
- 换手率 8585.97%
- 52周最低 10.415
- 委 比 -15.62%
- 总股本 8.75万
- 历史最高 181.83
- 量 比 1.53
- 振 幅 35.02%
- 历史最低 1.10
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crude Oil Moves Lower; Cintas Raises FY2026 Forecast
The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp posted strong earnings and raised its forecast, while Sarepta Therapeutics and Braze Inc saw significant gains.
03-26 03:36
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings
US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics surges 29%. Oil down 2.1%, gold up 3.2%.
03-26 02:16
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs
Sarepta stock slips after FDA update and mixed trial results, as investors weigh approval hopes against weak data signals.
03-19 23:51
Sarepta CEO To Jump Ship After 'Tumultuous' Year
Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.
02-26 18:52
Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday?
Natural gas jumps over 30% on winter storm disruptions, silver posts its biggest daily surge since 2008, and stocks grind higher.
01-27 02:26
Sarepta Says Elevidys Slows Duchenne Progression After Three Years
Sarepta's Elevidys shows significant improvement in motor function measures after three years of treatment, with no new safety signals.
01-26 22:26
Dyne's Duchenne Drug Shows Strong Muscle And Function Improvements
Dyne Therapeutics reported positive results from Phase 1/2 DELIVER trial for z-rostudirsen in DMD amenable to exon 51 skipping.
2025-12-09 02:37
Silver Soars Past $58, Bitcoin-Strategy Bloodbath Deepens: What's Moving Markets Monday?
Wall Street kicked off December with stocks slightly easing after a strong late-November rally, as rising global bond yields and sharp moves in commodities and crypto set a more cautious tone for equity traders.
2025-12-02 02:25
Arrowhead Pharmaceuticals Earns $200M Milestone Payment From Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone was earned when Arrowhead achieved the second
2025-11-24 20:31
Sarepta Shares Jump After FDA Approves Updated Elevidys Label
Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys.
2025-11-15 06:48
